The Eukaryotic Vault: An Enduring Enigma from Cellular Structure to Nanotechnological Frontier – A 2025 Perspective

Section 1: Introduction

Vaults are remarkably large and highly conserved ribonucleoprotein (RNP) complexes, ubiquitously found in the cytoplasm of most eukaryotic cells. First identified nearly four decades ago, these intricate cellular structures have captivated and perplexed researchers in equal measure. Their unique architecture, evolutionary persistence, and sheer abundance within cells suggest fundamental biological roles. However, the precise nature of these functions has remained one of the most enduring enigmas in modern cell biology. It is important to clarify at the outset that early nomenclature sometimes referred to these structures imprecisely; the correct and accepted term for these organelles is simply "vaults," and any reference to terms such as "ascending vault" should be considered a misnomer.

This report aims to provide a comprehensive analysis of the eukaryotic vault organelle, synthesizing the current understanding as of June 1, 2025. It will delve into the history of their discovery, their complex structure and molecular composition, and their intriguing evolutionary trajectory. Furthermore, this analysis will critically examine the diverse cellular processes in which vaults have been implicated, the insights gleaned from genetic knockout models, and the leading hypotheses regarding their elusive functions. Finally, the report will explore the burgeoning field of vault nanotechnology, where these enigmatic particles are being ingeniously engineered for a myriad of biomedical and biotechnological applications, and will consider the future directions paramount to finally unraveling the secrets of this key challenge in eukaryote biology.

Section 2: Discovery and Evolutionary Perspective

The journey to understand vaults began with an unexpected observation, leading to the realization that these particles are ancient components of eukaryotic cells, though curiously absent in some major lineages.

2.1. A Serendipitous Discovery

The vault organelle was first identified and isolated in 1986 by Nancy Kedersha and Leonard Rome.[1] Their discovery was serendipitous, occurring during attempts to purify clathrin-coated vesicles from rat liver homogenates.[3] Among the vesicle preparations, Kedersha and Rome observed distinct, contaminating particles with a unique

morphology.[4] When viewed under an electron microscope after negative staining, these structures resembled the repeating, arched ceilings of cathedrals, prompting the name "vaults".[1] This characteristic appearance, with its implied structural complexity, immediately signaled the presence of a novel cellular entity.

2.2. Evolutionary Conservation and Distribution

Vaults exhibit a high degree of conservation in terms of size, structure, and composition across the eukaryotic species in which they are found.[1] This conservation implies a significant, evolutionarily selected function. Phylogenetic analyses, including those using ancestral sequence reconstruction for the Major Vault Protein (MVP), suggest that vaults were likely present in the Last Eukaryotic Common Ancestor (LECA).[7] Evidence for MVP, and thus vaults, has been found in diverse eukaryotic supergroups, including Opisthokonts (which encompass animals), Amoebozoa, Excavates, and Chromalveolates.[7] The Pfam database's vault model further identifies MVP homologues in a wide array of organisms such as *Paramecium tetraurelia*, Kinetoplastida, many vertebrates, cnidarians (e.g., starlet sea anemone), molluscs, *Trichoplax adhaerens*, flatworms, *Echinococcus granulosus*, and Choanoflagellates.[2]

Despite this widespread distribution and ancestral origin, vaults appear to have been lost in several prominent eukaryotic lineages. These include most fungi (such as the model yeast *Saccharomyces cerevisiae*), insects (like the fruit fly *Drosophila melanogaster*), and nematodes (e.g., *Caenorhabditis elegans*).[2] The absence in land plants (e.g., *Arabidopsis thaliana*) is also noted, although some algal sequences suggest a more complex picture in the broader plant kingdom.[2] The reasons for these specific evolutionary losses are speculative and may relate to alternative cellular strategies developed in these groups, such as different feeding mechanisms or symbiotic relationships that obviate the need for vault functions.[7] Intriguingly, computational studies have identified homologs of MVP in bacteria, with cyanobacterial sequences showing the most similarity, suggesting an even deeper evolutionary history for vault-related proteins.[2]

2.3. Prevalence in Eukaryotic Cells

In organisms that possess them, vaults are not rare curiosities but are present in substantial numbers. They are found in most eukaryotic cells and are a consistent feature of all higher eukaryotes.[1] Estimates of their abundance range from 104 to 107 particles per cell, depending on the cell type and its metabolic state.[1] More specific figures often cite around 10,000 to 100,000 vaults per typical mammalian cell [3], with some immune cells, like macrophages, potentially containing even higher numbers.[3] This high copy number further underscores their likely importance in cellular

physiology.

Section 3: The Architecture of the Vault: Structure and Composition

The vault organelle is defined by its remarkable size and intricate, symmetrical architecture, assembled from a specific set of protein and RNA components. Recent structural studies continue to refine our understanding of its detailed morphology.

3.1. Gross Morphology and Dimensions

Vaults are the largest known ribonucleoprotein particles in eukaryotic cells.[1] They possess a characteristic hollow, barrel-like structure, formed by two identical, cup-shaped halves that join at their open ends, creating a central lumen.[1] This construction suggests a dynamic nature, with the potential for the particle to open and close in response to cellular cues.[1]

The dimensions of the vault particle are considerable, measuring approximately 72.5 nm in length and 41 nm in diameter as determined by some studies [1], though slight variations exist depending on the imaging modality: 34 nm x 60 nm from negative staining, 26 nm x 49 nm from cryo-electron microscopy (cryo-EM), and 35 nm x 59 nm from scanning transmission electron microscopy (STEM).[2] The molecular mass of the entire complex is approximately 13 MDa, roughly three times that of a eukaryotic ribosome.[1] The internal volume is estimated to be around 5×104 nm3 [1] or 50 million Å3 [7], providing a substantial space potentially for sequestering cargo. The vault exhibits a striking 39-fold (or D39d) rotational symmetry around its longitudinal axis.[2] Due to being composed primarily of protein (over 95% by mass), vaults are difficult to visualize with conventional electron microscopy stains that target nucleic acids or lipids, which contributed to their late discovery.[2]

3.2. Core Components

The vault particle is a complex assembly of a major protein component, two minor proteins, and at least one species of RNA.

3.2.1. Major Vault Protein (MVP): The Structural Scaffold

The Major Vault Protein (MVP) is the primary building block of the vault shell, constituting over 70% of the particle's total mass.[1] Each MVP monomer is a protein of approximately 100 kDa (variously reported as ~97 kDa [15], 100 kDa [2], 104 kDa [20], or ~110 kDa [20]). A total of 78 copies of MVP self-assemble to form the complete barrel-shaped structure, with each of the two half-vaults composed of 39 MVP monomers.[2]

Expression of MVP alone in insect cells is sufficient for the assembly of vault-like particles, highlighting its intrinsic self-assembly properties.[2]

The MVP subunit has a defined domain structure: from the N-terminus to the C-terminus, it folds into nine repeat domains (R1-R9), a band7-like shoulder domain (also referred to as SPFH domain), a cap-helix domain, and a cap-ring domain.[2] These domains correspond to the overall shape of the vault shell, with the N-termini of the MVP molecules from each half-vault meeting at the particle's central waist.[2] Genetic knockout of the MVP gene in mice results in the absence of detectable vault particles, confirming its essential structural role.[20]

3.2.2. Minor Vault Proteins: VPARP and TEP1

Associated with the MVP shell are two less abundant, but significant, protein components:

- **Vault Poly(ADP-ribose) Polymerase (VPARP/PARP4):** VPARP, also known as PARP4, is a large protein with a molecular weight of 193 kDa.[2] It is a member of the poly (ADP-ribose) polymerase (PARP) family and is the only vault component identified to date with a known enzymatic activity.[17] VPARP retains its catalytic function within purified vaults, where it can ADP-ribosylate itself and also MVP.[17] This enzymatic activity involves the production of short polymers of ADP-ribose units.[17] While a significant portion of VPARP is associated with cytoplasmic vaults, subpopulations are also found in the nucleus and at the mitotic spindle, suggesting functions beyond the vault particle itself.[18] Structurally, VPARP binds to the fourth repeat domain (R4) of MVP.[2] Mice deficient in VPARP are viable and fertile, possess structurally intact vaults, and show no major defects in telomerase function.[11] However, these knockout mice exhibit an increased incidence of carcinogen-induced colon tumors [4] and, in some contexts, slightly raised tumor growth when tumors are induced.[4]
- **Telomerase-Associated Protein 1 (TEP1):** TEP1 is another large protein component, with reported molecular weights of 240 kDa [17] or 290 kDa.[2] As its name suggests, TEP1 is also a component of the telomerase ribonucleoprotein complex, which is involved in maintaining chromosome ends.[1] However, disruption of TEP1 alone in mice does not appear to affect telomere length or telomerase activity significantly.[11] Within the vault particle, TEP1 plays a critical role in the binding, localization, and stability of vault RNAs (vRNAs).[4] The absence of TEP1 leads to a complete disruption of the stable association of vRNA with purified vaults and a decrease in vRNA levels and stability.[25] TEP1 contains WD40 repeats that allow it to form a ring structure, and it binds to the cap domain of MVP.[2] Similar to VPARP-deficient mice, TEP1-deficient mice are viable and show no

major telomere-related issues, but they do exhibit reduced vRNA stability.[23] TEP1 deficiency has also been linked, albeit to a lesser extent than VPARP deficiency, to an increased incidence of carcinogen-induced colon tumors.[20]

3.2.3. Vault RNA (vRNA / vtRNA): Structure, Diversity, and Association

Vaults in higher eukaryotes also contain one or several small, untranslated RNA molecules known as vault RNAs (vRNAs or vtRNAs).[1] These RNAs are typically 86 to 141 bases in length and are transcribed by RNA polymerase III.[2] Structurally, vRNAs fold into a secondary structure characterized by conserved stem-loops that connect the 5' and 3' ends of the molecule, often described as forming a panhandle-like shape.[27] They also contain internal RNA polymerase III promoter elements, specifically box A and box B motifs.[16]

Cryo-electron microscopy studies have localized vtRNAs near the end caps of the vault particle, a position that would allow them to interact with both the interior and exterior of the vault.[25] Their association with the vault and their stability are critically dependent on TEP1.[25] It is generally believed that vtRNAs serve a functional rather than a structural role within the vault complex.[27] Interestingly, some evidence suggests that a significant proportion (more than 95%) of cellular vRNAs may not be directly associated with the vault protein complex, hinting at potential independent functions for these RNA molecules.[10]

The types and lengths of vtRNAs can vary between species. Humans express at least three related vtRNAs: hvg1 (98 bases, the most abundant), hvg2 (88 bases), and hvg3 (88 bases).[16] Rats and mice express a single, longer vtRNA of 141 bases [20], while bullfrogs express two vtRNAs of 89 and 94 bases respectively.[27]

3.3. Advanced Structural Revelations (as of June 2025)

Recent advancements in cryo-electron microscopy continue to provide unprecedented detail about vault architecture, particularly concerning the previously unresolved cap structures.

Cryo-EM Insights into Vault Caps: Symmetry Mismatch and Pore Formation (Lövestam & Scheres, May 2025)

A significant recent development is a bioRxiv preprint from May 2025 by Lövestam and Scheres, which describes the cryo-EM structure of vault particles isolated (as a contamination) from human brain tissue of an individual with progressive supranuclear palsy.[21] This study achieved an overall resolution of 3.1 Å for the main vault body imposing D39 symmetry, revealing a structure nearly identical to previously reported

"primed state" vault structures.[21]

The most striking finding is the elucidation of a "symmetry mismatch" at the vault caps.[21] While the main body of the vault exhibits the established 39-fold rotational symmetry, this transitions to a 13-fold symmetry specifically at the caps.[21] This symmetry transition is achieved through a mechanism whereby two out of every three MVP monomers are sequentially excluded from participating in the cap structure. Specifically, in one monomer type (monomer A), the long α-helix that typically spans residues 803-823 in the other two monomer types breaks at residue 813, causing the chain to fold inwards towards the vault lumen.[21]

This sequential exclusion and conformational change result in the formation of a "narrow, greasy pore" at the very tip of each vault cap.[21] Focused 3D classification techniques were employed to resolve the cap structure to 3.6 Å, as the C-terminal residues of MVP (801-893) were smeared in the initial D39 reconstruction.[21] The first eleven N-terminal residues of MVP and any potential encapsulated cargo were not observed in this structure.[21]

The discovery of this defined pore and the mechanism of its formation via symmetry mismatch has profound implications. It provides a tangible structural feature that could mediate the long-hypothesized opening, closing, and cargo transport functions of the vault. The "greasy," or hydrophobic, nature of the pore is particularly suggestive. Vaults have been implicated in multidrug resistance, often involving hydrophobic chemotherapeutic drugs [1], and have been found enriched in lipid rafts, which are lipid-rich membrane microdomains.[7] A hydrophobic pore could provide a selective passage for such molecules or facilitate interaction with lipidic environments. This detailed structural insight moves the discussion from whether vaults transport cargo to *how* they might transport specific types of cargo. Furthermore, these findings offer valuable insights for the rational engineering of MVP, particularly its C-terminal region, for therapeutic applications, potentially allowing for controlled encapsulation and release of drugs or other biomolecules.[21]

A summary of the core components is presented in Table 1.

Table 1: Key Molecular Components of the Eukaryotic Vault

Component	Molecular Weight (kDa or bases)	Number of Copies per Vault (approx.)	Key Known Functions/Interactions within	Primary References

			Vault	
Major Vault Protein (MVP)	~100 (97-110) kDa	78	Forms the structural shell; self-assembles; interacts with VPARP, TEP1, and potentially cargo; N-termini at waist, C-termini form caps with pores.	[1]
Vault Poly(ADP-ribose) Polymerase (VPARP / PARP4)	193 kDa	~8 (estimates vary, e.g. 2-8)	Enzymatic activity (ADP-ribosylation of self and MVP); binds MVP repeat domain 4; dispensable for vault structure *in vivo*.	[2]
Telomerase-Associated Protein 1 (TEP1)	240 or 290 kDa	~2 (estimates vary, e.g. 2)	Binds MVP cap domain; crucial for vRNA binding, localization, and stability within the vault; shared with telomerase complex.	[2]
Vault RNA (vRNA / vtRNA)	86-141 bases (species-dependent)	At least 6 (estimates vary)	Small, untranslated RNA; located near vault caps; interacts with TEP1; presumed functional role (e.g., drug binding, regulation); >95% may be	[2]

			free in cytoplasm.	

Section 4: The Quest for Function: Unraveling the Vault's Cellular Roles

Despite nearly four decades of research since their discovery, and detailed knowledge of their structure, abundance, and evolutionary conservation, the precise cellular function or functions of vault organelles remain largely elusive.[2] This persistent mystery is a central theme in vault biology.

4.1. The Persistent Mystery: Challenges in Elucidating Vault Function

Several key challenges have hampered efforts to definitively assign functions to vaults:

- **Lack of Severe Phenotypes in Knockout Models:** Genetic ablation of individual vault protein components (MVP, TEP1, VPARP) or even the creation of completely vaultless mice has, surprisingly, not resulted in severe, overt phenotypes under standard laboratory conditions.[2] This suggests that either vaults perform non-essential functions, their roles are highly redundant with other cellular pathways, or their importance only becomes apparent under specific, uninvestigated physiological or stress conditions.
- **Absence in Key Model Organisms:** Vaults are notably absent in some of the most genetically tractable and widely used model organisms, including the yeast *Saccharomyces cerevisiae*, the nematode *Caenorhabditis elegans*, and the fruit fly *Drosophila melanogaster*.[2] This has limited the application of powerful genetic screening tools commonly employed in these systems.
- **Biochemical Properties:** The predominantly proteinaceous nature of vaults made them difficult to stain with conventional nucleic acid or lipid stains used in early electron microscopy studies, contributing to their late discovery and potential misidentification as other cellular bodies like glycogen particles.[3]
- **Rapid Assembly Dynamics:** The major vault protein (MVP) exhibits a strong tendency to self-assemble into particles, meaning there is virtually no free MVP in the cell.[13] This makes it challenging to investigate potential functions of unassembled MVP or to target it for functional inactivation before it incorporates into vaults.
- **Funding Difficulties:** The slow progress in definitively elucidating vault function has, at times, led to challenges in securing sustained research funding for basic investigations into their biology.[3]

4.2. Implicated Cellular Processes

Despite the overarching mystery, vaults have been implicated in a broad array of cellular functions, often based on their localization, interacting partners, or changes in their expression levels in different physiological or pathological states.

4.2.1. Nucleocytoplasmic Transport and Nuclear Pore Complex (NPC) Association

Early observations of the vault's octagonal symmetry at its caps, reminiscent of the nuclear pore complex (NPC), and their frequent localization near the nuclear envelope, led to speculation about a role in nucleocytoplasmic transport.2 Indeed, studies have shown vaults localized to both the cytoplasm and the nucleus.19 In primate and rodent cerebral cortex, MVP is found on both the cytoplasmic and nucleoplasmic faces of the nuclear envelope, often in direct association with NPCs.19

More direct functional evidence comes from experiments using a cell-free system derived from Xenopus egg extracts. These studies demonstrated that MVP is unexpectedly required for the de novo assembly and insertion of NPCs into preformed, pore-free nuclear envelopes.33 This finding strongly implicates MVP, and by extension vaults, in the biogenesis of NPCs, providing a functional rationale for their observed proximity to these critical transport channels.

4.2.2. mRNA Localization and Transport

Vaults have also been implicated in the localization and transport of messenger RNAs (mRNAs).[2] In cortical neurons, MVP is expressed along the nucleus-neurite axis and associates with microtubules, which serve as tracks for intracellular transport.[19] Immunoprecipitation of MVP from neuronal extracts has been shown to co-precipitate specific mRNAs, such as those encoding tissue plasminogen activator (tPA) and striatal-enriched tyrosine phosphatase (STEP), which are known to be translated locally in dendrites in response to synaptic activity.[19] Importantly, these associated mRNAs appear to be protected within the vault structure [19], suggesting a role for vaults in the targeted transport and protection of specific mRNAs to distinct subcellular locations, such as along neurites for local protein synthesis. While some broader hypotheses by Rome regarding general mRNA transport by vaults were explored extensively, they did not yield conclusive results for a universal role.[11] Nevertheless, observations of vaults containing cargo suggested to be mRNA lend support to this area of investigation.[7]

4.2.3. Multidrug Resistance (MDR) and Cancer

One of the most extensively studied, yet still debated, roles of vaults is in multidrug resistance (MDR) in cancer cells. The major vault protein (MVP) was independently identified as the Lung Resistance-related Protein (LRP).30 Overexpression of MVP/LRP is frequently observed in a wide variety of chemoresistant cancer cell lines and primary human tumors, and this

overexpression often correlates with poor patient prognosis and resistance to chemotherapy.1
Several mechanisms have been proposed for how vaults might contribute to MDR:

- **Drug Transport and Sequestration:** The hollow structure of the vault has led to the hypothesis that they might act as transporters, sequestering cytotoxic drugs away from their intracellular targets (e.g., the nucleus or DNA) or facilitating their efflux from the cell.[1] This has been suggested for drugs like doxorubicin, cisplatin, mitoxantrone, and bleomycin.
- **vRNA-Drug Interaction:** Specific vault RNAs, notably vtRNA1-1 and vtRNA1-2, have been shown to directly bind to chemotherapeutic agents such as mitoxantrone, potentially sequestering them and reducing their efficacy.[1]
- **svRNA-Mediated Regulation:** Vault RNAs can be processed by the DICER enzyme into small vault RNAs (svRNAs). These svRNAs can then function similarly to microRNAs (miRNAs), for instance, by binding to an Argonaute protein and down-regulating the expression of enzymes like CYP3A4, which is involved in drug metabolism.[27]

However, the role of vaults in MDR is complex and not without controversy. Studies involving MVP knockout mice or cells derived from them have not consistently demonstrated increased sensitivity to chemotherapeutic drugs.[3] This suggests that the contribution of vaults to MDR might be cell-type specific, dependent on the particular drug, or require the interplay of other cellular factors.[30]

4.2.4. Cell Signaling Pathways

Vaults and their components, particularly MVP and vtRNAs, have been implicated in the regulation of a multitude of crucial cell signaling pathways that affect processes such as tumor survival, proliferation, apoptosis, and metastasis.1
Examples of these pathways include:

- The MAP kinase (ERK) pathway: MVP may act as a scaffold for ERK.[19]
- The JAK/STAT pathway: MVP expression can be regulated by this pathway, and MVP itself can influence STAT signaling (e.g., STAT6 in macrophage polarization, STAT3 inhibition in some lung cancers).[35]
- The Phosphoinositide 3-kinase (PI3K)/Akt pathway: MVP interacts with the tumor suppressor PTEN, a key negative regulator of this pathway.[20]
- The mTOR/S6K1 pathway: MVP can regulate GLI1 expression via this cascade in chondrosarcoma.[35]
- The NF-κB pathway: MVP has been identified as a suppressor of NF-κB signaling in macrophages.[35]
- The Notch1 pathway: Notch1 can activate the AKT pathway and promote epithelial-mesenchymal transition (EMT) partly through direct activation of MVP.[35]

These interactions position vaults as potential modulators of complex signaling networks.

4.2.5. Innate Immunity and Inflammatory Responses

A growing body of evidence links vaults to innate immunity and inflammatory responses.[2]

- MVP function has been connected to the TNFα-mediated maturation of monocytes into dendritic cells (DCs), which are critical antigen-presenting cells.[38] MVP expression also increases during DC development in murine models.[39]
- MVP knockout mice exhibit increased susceptibility to infection by the bacterium *Pseudomonas aeruginosa*, which is attributed to an impaired NF-κB signaling pathway, reduced IL-8 secretion, and altered apoptosis in these animals.[20]
- MVP expression can be activated by interferon-γ (IFN-γ) through the JAK/STAT pathway.[20]
- Furthermore, the expression of vault RNAs (vtRNAs) is dramatically induced in response to infection with the Epstein-Barr virus (EBV), suggesting a role for vaults or vtRNAs in antiviral defense mechanisms.[20]

4.2.6. Autophagy Regulation

Recent findings have highlighted a role for vtRNAs, particularly vtRNA1-1, as riboregulators of autophagy and lysosome-mediated chemotherapy resistance.[4] Autophagy is a fundamental cellular process for degrading and recycling damaged organelles and proteins. It is reported that vtRNA1-1 can bind to the autophagic receptor protein p62 (also known as SQSTM1), thereby inhibiting its function, especially under conditions of cellular stress or starvation. A reduction in vtRNA1-1 levels is associated with decreased binding to p62, which promotes p62 oligomerization and enhances autophagic flux.[10] In the context of endocrine tumors, the upregulation of vault complex components and the specific exosomal release of vault RNAs have been directly correlated with therapeutic responsiveness and the modulation of autophagy.[10]

4.2.7. DNA Damage Response and Repair

There are indications that vaults may participate in the cellular response to DNA damage and subsequent repair processes. MVP transcription and protein levels have been observed to increase in response to various DNA-damaging agents, including ionizing radiation.[20] Furthermore, mice deficient in VPARP and, to a lesser extent, TEP1 show an increased incidence of carcinogen-induced colon tumors.[4] These findings

suggest that intact vault components may play a role in facilitating DNA repair processes or maintaining genomic stability. MVP has also been reported to associate with components of the major DNA double-strand break repair machineries, namely non-homologous end joining (NHEJ) and homologous recombination (HR).[20]

4.3. Insights from Knockout Models

The development of genetic knockout models, primarily in mice and the slime mold *Dictyostelium discoideum*, has been crucial in attempts to decipher vault function, though the results have often added to the complexity.

4.3.1. Mammalian Models (Mice)

- **MVP Knockout (MVP-/-):** Mice lacking MVP are also devoid of detectable vault particles.[20] These mice are generally viable, fertile, and appear phenotypically normal under standard laboratory conditions, with no gross developmental abnormalities.[2] Contrary to expectations based on *in vitro* studies, MVP-/- mice and cells derived from them do not consistently show increased sensitivity to various chemotherapeutic drugs.[3] However, they do exhibit increased susceptibility to certain infections, such as lung infection with *Pseudomonas aeruginosa*.[20] Despite the high expression of MVP in wild-type dendritic cells, MVP-/- mice show no significant impairment in dendritic cell migration or antigen presentation capabilities.[20]
- **TEP1 Knockout (mTep1-/-):** Mice deficient in TEP1 are viable and exhibit no apparent changes in telomere length or telomerase activity over multiple generations.[11] The primary phenotype observed is a disruption of vRNA association with vaults and a significant reduction in vRNA stability and overall levels.[23] Similar to VPARP KO mice, TEP1 KO mice also show an increased incidence of carcinogen-induced colon tumors, although possibly to a lesser extent.[20]
- **VPARP Knockout (mVparp-/-):** Mice lacking VPARP are also viable and fertile. They possess structurally intact vault particles and show no major defects in telomerase activity or telomere length maintenance.[11] However, these mice have been reported to exhibit slightly raised tumor growth when tumors are experimentally induced [4] and a significantly increased incidence of carcinogen-induced colon tumors.[20]
- **Combined TEP1/VPARP Knockout:** Mice deficient in both TEP1 and VPARP do not display any additional telomerase or telomere-related phenotypes beyond those seen in the single knockout animals.[23]
- **Completely Vaultless Mice:** Mice in which all three vault protein components (MVP, TEP1, and VPARP) have been knocked out, rendering them completely

devoid of vaults, are also reported to be phenotypically normal under standard conditions. However, they are described as having some "subtle immune system issues," though the precise nature of these issues is not extensively detailed in the available information.[4]

4.3.2. *Dictyostelium discoideum*

The social amoeba *Dictyostelium discoideum* is a simpler eukaryote that possesses vaults and encodes three different MVPs (mvpA, mvpB, and a third less characterized one).[2] Knockout studies in this organism have provided some clues. A double knockout of two MVP genes (*mvpA* and *mvpB*) resulted in a distinct phenotype: growth retardation specifically under conditions of nutritional stress.[2] This is, to date, the most clearly defined phenotype associated with vault loss in *Dictyostelium* under specific challenge conditions.

A summary of these knockout phenotypes is presented in Table 2.

Table 2: Summary of Phenotypic Observations in Vault Component Knockout Organisms

Organism/Cell Type	Gene(s) Knocked Out	Key Phenotypic Observations (Normal Conditions)	Phenotypes Under Stress/Challenge	Implied Functional Role	Primary References
Mouse (Mus musculus)	MVP	Viable, fertile, phenotypically normal; no detectable vault particles.	Increased susceptibility to *Pseudomonas aeruginosa* infection; no consistent change in drug sensitivity; no impairment in DC migration/antigen presentation.	Role in innate immunity (NF-$\kappa $B signaling, IL-8 secretion); potential minor role in drug resistance (context-dependent); not essential for basic viability or	[2]

				DC function.	
Mouse (Mus musculus)	TEP1	Viable, fertile; no change in telomere length/telomerase activity.	Disrupted vRNA association with vaults, reduced vRNA stability/levels; increased incidence of carcinogen-induced colon tumors (lesser extent than VPARP KO).	Essential for vRNA stability and association with vaults; potential role in genomic stability/tumor suppression.	[11]
Mouse (Mus musculus)	VPARP	Viable, fertile; intact vaults; no major telomerase defects.	Slightly raised tumor growth when induced; increased incidence of carcinogen-induced colon tumors.	Potential role in tumor suppression/genomic stability; dispensable for vault structure and telomerase function.	[4]
Mouse (Mus musculus)	TEP1 and VPARP (Combined)	Viable.	No additional telomerase/telomere phenotypes beyond single KOs.	Suggests non-overlapping primary roles of TEP1 and VPARP in telomere maintenance, and that their combined loss does not synergistically impact this process	[23]

				more than individual losses.	
Mouse (Mus musculus)	MVP, TEP1, VPARP (Complete)	Phenotypically normal.	Some "subtle immune system issues" (details limited).	Suggests vaults are not essential for gross development or health under normal conditions, but may play nuanced roles in immune function.	[4]
Dictyosteliu m discoideum	Two MVP genes (e.g., mvpA, mvpB)	Normal growth under nutrient-rich conditions.	Growth retardation under nutritional stress.	Role in adaptation to or survival under nutritional stress.	[2]

The often subtle or condition-specific nature of these knockout phenotypes, combined with the extensive list of cellular processes vaults are implicated in, leads to a compelling consideration: vaults may not possess a single, dedicated primary function in the classical sense. Instead, their biological significance might arise from their capacity to act as versatile platforms or modulators that integrate into and influence multiple cellular pathways. The specific role they play could be highly dependent on the cellular context, the nature of environmental or physiological stress, and the network of interacting molecules present at any given time. This "multi-functional modulator" or "cellular hub" concept could explain their evolutionary conservation (being broadly useful in many contexts) and the difficulty in pinpointing one indispensable role, as their importance might fluctuate with cellular needs and be subject to compensatory mechanisms. Research might therefore benefit from focusing less on identifying *the* singular function and more on comprehensively mapping their interaction networks and conditional activities across diverse cellular states.

4.4. Current Leading Hypotheses (June 2025)

Given the complex web of associations, several leading hypotheses about vault function persist:

- **Leonard Rome's Hypotheses:**
  - **Cytoplasmic Coordination:** One of the prominent ideas from their discoverer, Leonard Rome, is that vaults may play a role in coordinating activities within the cell cytoplasm. This could involve interactions with, or organization of, transient membrane-less organelles such as stress granules and processing bodies, particularly in response to cellular stresses like viral infection or the development of cancer.[4]
  - **"Cellular Caches" / "Rocks" for Amino Acids:** Another more recent hypothesis proposed by Rome, which he indicates warrants further exploration, is that vaults, given their substantial proteinaceous mass, might serve as a form of bulk storage for amino acids. This would be analogous to how glycogen particles function as storage for glucose.[11]
- **Other Emerging Functional Paradigms:**
  - **"Sentinel Hypothesis":** This idea has emerged from studies employing CRISPR-Cas9 knockout of MVP in zebrafish. The findings suggest that MVP, and by extension vaults, might be primarily responsible for orchestrating inflammatory or stress responses, acting as "sentinels" that detect and react to cellular perturbations.[41] This aligns well with the observed links between vaults and the immune system.
  - **General Stress Response Hubs:** Considering their implication in MDR, immune responses, autophagy regulation, and DNA damage responses, a broader hypothesis is that vaults function as general stress response particles. They could act as hubs that integrate various stress signals and help coordinate appropriate cellular defense mechanisms.[1]

Section 5: Vaults in Human Health and Disease: Beyond Multidrug Resistance

The involvement of vaults extends beyond their debated role in multidrug resistance, touching upon various aspects of cancer biology and other human pathologies.

5.1. The Role of Vaults in Cancer Biology

The connection between vaults and cancer is multifaceted:

- **Multidrug Resistance and Prognosis:** As extensively discussed, the overexpression of MVP/LRP is a frequent hallmark of chemoresistant cancers,

including colorectal, ovarian, and lung carcinomas, as well as acute myeloid leukemia (AML) and prostate cancer. This overexpression often correlates with a poorer prognosis for patients.[1]

- **Tumor Cell Behavior:** MVP has been shown to play a role in promoting tumor cell proliferation, migration, and metastasis in several cancer types.[1] For instance, MVP expression facilitates tumor cell proliferation and migration, supporting the metastasis of colorectal cancer cells.[35]
- **Modulation of Oncogenic Signaling:** Vault components, including both MVP and vtRNAs, actively modulate critical oncogenic signaling pathways. Examples include MVP regulating the polarization of tumor-associated macrophages through interaction with STAT6 [35], and influencing constitutive GLI1 expression in chondrosarcoma via the mTOR/S6K1 signaling cascade.[35]
- **vtRNAs in Cancer Processes:** Vault RNAs contribute to cancer biology by modulating cell proliferation, apoptosis, and autophagy within the tumor context.[10]

However, the role of MVP in cancer is not uniformly pro-tumorigenic. In a notable exception, some studies on non-small cell lung cancer (NSCLC) found that higher MVP expression correlated with *better* clinical outcomes. In this context, MVP was suggested to act as a lung tumor suppressor, potentially by inhibiting the STAT3 pathway.[35] This highlights a significant context-dependency in vault function. Such contrasting roles—MVP promoting aggression in many cancers yet potentially acting as a tumor suppressor in others—underscore that the impact of vaults is not intrinsic but is heavily influenced by the specific cellular milieu, the tumor microenvironment, and the array of active signaling networks. This complexity means that if vaults or their components are to be considered therapeutic targets or biomarkers, a nuanced, cancer-type-specific approach will be essential. Predicting whether to inhibit or augment vault activity would require a deep understanding of their operational context in each specific malignancy.

5.2. Implications in Other Pathologies

Beyond cancer, vaults and their components have been implicated in a range of other human diseases and physiological conditions:

- **Neurodegenerative Diseases:** While direct, causative links are still largely unexplored, the established role of MVP in neuronal mRNA transport [19] and its interaction with proteins like PTEN (which has known roles in neuronal function and dysfunction) [20] suggest potential avenues for investigation. The recent cryo-EM study by Lövestam and Scheres utilized human brain tissue from an individual with progressive supranuclear palsy (PSP), although the vaults

themselves were identified as contaminants in a preparation to extract tau filaments.[21] Furthermore, research is ongoing into the connection between the p97 AAA-ATPase (implicated in neurodegenerative diseases) and the vault-associated PARP4 (VPARP).[42]

- **Viral Infections:** Vault RNAs (vtRNAs) see a dramatic induction in expression following infection with the Epstein-Barr virus (EBV).[20] Vaults, in general, have been associated with the immunological response to several human viral pathogens, and it has been suggested that MVP/vaults could be involved in broader antiviral defense mechanisms.[20]
- **NSUN2 Deficiency Disease:** Vault non-coding RNAs contain multiple cytosine residues that are normally methylated by the NSUN2 protein. In cells deficient in NSUN2, the loss of this cytosine-5 methylation leads to the incorrect processing of vtRNAs into small RNA fragments that can function similarly to microRNAs. It has been suggested that this impaired vault RNA processing may contribute to the symptoms manifested in NSUN2 deficiency diseases.[27]
- **Epilepsy:** Vaults are known to be upregulated in the context of epilepsy, although the functional significance of this observation is not yet clear.[7]
- **Inflammatory Conditions and Metabolic Disease:** MVP expression is upregulated in macrophages found in the visceral adipose tissue of obese individuals (both humans and mice). This upregulation correlates with obesity and associated inflammation. Studies suggest that macrophage MVP may act as a key constraint of NF-κB signaling, thereby playing a role in suppressing metabolic diseases.[35]

Section 6: Engineering the Enigma: Vault Nanoparticles in Biotechnology and Medicine

Despite the enduring mystery surrounding their natural functions, the unique structural properties of vaults have made them highly attractive candidates for development as a bioinspired nanoplatform. Their uniform size, inherent biocompatibility, robust self-assembly from MVP, and hollow lumen capable of encapsulating diverse molecules offer a compelling toolkit for nanotechnologists and biomedical engineers.[2]

6.1. Vaults as a Bioinspired Nanoplatform: Design and Engineering Principles

The capacity of MVP to self-assemble into vault particles when expressed (e.g., in baculovirus-infected insect cells) forms the basis of vault nanotechnology.[2] This allows for the production of recombinant vaults that can be engineered by genetically modifying the MVP gene. These modifications can introduce:

- **Packaging Signals:** Specific peptide sequences, such as the INT domain derived from VPARP, can be fused to proteins of interest to direct their packaging into the vault lumen during assembly.[32]
- **Targeting Moieties:** Ligands or antibody-binding domains can be attached to the vault surface to direct them to specific cells or tissues. For example, fusing the Z-domain of protein A (which binds the Fc region of IgG antibodies) to the C-terminus of MVP allows vaults to be decorated with antibodies targeting specific cell surface antigens.[36]
- **Cell Penetration Peptides:** Sequences like the TAT peptide from HIV-1, when fused to the C-terminus of MVP, significantly enhance the cellular uptake and internalization of vault nanoparticles.[9]
- **Modified Cargo Interaction:** Fusing amphipathic helices (e.g., from the hepatitis C virus NS5A protein) to the N-terminus of MVP can create lipophilic rings within the particle, enabling the selective binding and encapsulation of hydrophobic drugs.[36]
- **Enhanced Stability or Release Mechanisms:** Incorporating a cysteine-rich sequence at the N-terminus of MVP can enhance particle stability through the formation of disulfide bonds.[36] Fusing MVP with environmentally responsive polymers, such as N-isopropylacrylamide, allows for the creation of vaults that aggregate or disassemble (releasing cargo) in response to changes in temperature or pH (e.g., the acidic tumor microenvironment).[36]

These engineered modifications typically do not alter the basic barrel-shaped structure of the vault particle.[2]

6.2. Therapeutic Delivery Applications

The ability to encapsulate and protect molecular cargo makes engineered vaults promising vehicles for therapeutic delivery.

6.2.1. Drug Encapsulation and Targeted Delivery

Vaults can encapsulate a wide range of biomolecules, including proteins, peptides, and small molecule drugs, offering potential for controlled release and targeted delivery.[1]

- **RNA Therapeutics (siRNA, mRNA):** The potential for vaults to deliver RNA-based drugs, such as small interfering RNAs (siRNAs) or messenger RNAs (mRNAs), is an area of active interest.[14] A January 2025 article from CellGS highlights the prospect of improved delivery for RNA drugs loaded into empty vaults.[14] While general reviews from 2023-2025 emphasize the need for effective nanoparticle delivery systems for RNA therapeutics to overcome challenges like

instability and poor cellular uptake [45], specific examples of vault-mediated delivery of siRNA or mRNA with detailed targeting mechanisms from 2024-2025 are not extensively detailed in the provided information. However, a 2025 review by Maniatis et al. (literature search current to December 2024) reiterates that VPs are a promising platform for encapsulating a wide range of biomolecules and therapeutic agents.[36]

6.2.2. Gene Therapy: Vault-mediated AAV Delivery

A significant recent advancement (reported in a bioRxiv preprint by Collins, Curiel, et al. in February 2024, with revisions up to February 2024) involves the use of recombinant vault nanoparticles to deliver entire Adeno-Associated Viruses (AAVs).51 AAVs are common vectors in gene therapy, but their efficacy can be limited by pre-existing or induced neutralizing antibodies in patients.52

In this novel approach, AAVs were packaged inside engineered vaults (termed VAAVs) using the SpyTag-SpyCatcher molecular glue technology.51 The hypothesis is that the vault shell can shield the AAV from the host immune system. The study demonstrated that these VAAVs could successfully transduce cells even in the presence of anti-AAV neutralizing serum.51 This innovative strategy could potentially overcome a major hurdle in AAV-based gene therapy, allowing for effective treatment in patients with pre-existing immunity and enabling repeat dosing. This work is currently covered by a provisional patent.51

6.2.3. Vaccine Development (e.g., Vault Pharma's CCL21-based cancer immunotherapy – status June 2025)

Vaults can be engineered to display antigens on their surface or to encapsulate immunomodulatory molecules, making them attractive platforms for vaccine development.

- Vault Pharma, a company co-founded by Leonard Rome, is developing an engineered vault therapeutic for cancer. These vaults are designed to display the chemokine CCL21 on their surface.[4] CCL21 is known to attract dendritic cells and T-cells, key players in the anti-tumor immune response, to the tumor site. Clinical trials for this CCL21-vault therapeutic, initially targeting lung cancer, were planned to commence in 2025, with potential expansion to other cancer types.[3] As of June 2025, these trials are anticipated to be either underway or starting. Vault Pharma's corporate communications also indicate work on a Coronavirus vaccine candidate.[55]
- Preclinical studies have also shown success with other vaccine strategies. For example, engineered vaults carrying Chlamydia antigens were shown to provide protection against Chlamydia infection in mouse models when administered as a nasal spray.[56]

6.2.4. Strategies for Overcoming Multidrug Resistance

Beyond their debated natural role in MDR, engineered vaults offer potential therapeutic strategies to *overcome* drug resistance in cancer. This could involve using vaults to deliver agents that re-sensitize resistant cells to chemotherapy or to specifically target and kill resistant cancer cells.[1] For instance, while silencing MVP or other vault components has been shown in some contexts to increase drug sensitivity [24], engineered vaults could theoretically be used to deliver siRNAs targeting genes responsible for MDR. However, specific examples of this strategy being clinically advanced are not prominent in the provided materials, though the general concept aligns with the goals of siRNA delivery using nanoparticles.[1]

6.3. Applications in Synthetic Biology and Nanotechnology

The well-defined, self-assembling, and modifiable nature of vaults makes them versatile tools in broader synthetic biology and nanotechnology applications:

- **Nanoscale Containers and Scaffolds:** Vaults can serve as precisely structured nanoscale containers for various molecules or as scaffolds for assembling nanomachines or complex molecular arrays.[9]
- **Biosensing:** Engineered vaults could be designed as biological sensors, for example, to monitor specific conditions or analytes inside living cells.[2]
- **Enzyme Delivery and Bioreactors:** Vaults can encapsulate enzymes, protecting them and allowing for their delivery for applications such as *in situ* bioremediation (e.g., degrading environmental pollutants) or as contained bioreactors for specific chemical transformations.[2] For instance, enzymes like manganese peroxidase have been encapsulated in vaults, improving their stability without compromising catalytic activity for degrading organic pollutants.[4]
- **Nanoscale Electronics:** An early vision, articulated around 2005, suggested that vaults might even be used as structural elements for nanoscale machines or as switches for nanoscale electrical circuits, though this remains more conceptual.[32]

A summary of these applications is provided in Table 3.

Table 3: Current and Emerging Nanotechnological Applications of Engineered Vaults (June 2025)

Application Area	Specific Example/Strategy	Key Engineering Feature of	Current Status (June 2025)	Primary References

		Vault		
Therapeutic Delivery				
Drug Delivery (General)	Encapsulation of small molecules, peptides, proteins for controlled release.	MVP modification for cargo packaging (e.g., INT domain, amphipathic helices for hydrophobic drugs), enhanced uptake (TAT peptide), targeted release (polymers).	Preclinical; Ongoing Research & Development.	[9]
RNA Therapeutics (siRNA, mRNA)	Delivery of RNA drugs for gene silencing or protein expression.	Lumenal encapsulation, surface modification for targeting/uptake.	Conceptual/Early Preclinical for vaults; active field for general nanoparticles.	[14]
Gene Therapy	Vault-AAV (VAAV): AAV encapsulation to evade neutralizing antibodies.	SpyTag-SpyCatcher mediated AAV packaging within vault shell.	Preclinical (proof-of-concept demonstrated, patent pending).	[51]
Cancer Immunotherapy / Vaccines	CCL21-displaying vaults for attracting immune cells to tumors.	Surface display of CCL21 chemokine via MVP fusion.	Clinical Trials planned/commencing in 2025 (Vault Pharma).	[3]
Infectious Disease Vaccines	Delivery of pathogen antigens (e.g., Chlamydia).	Lumenal packaging or surface display of antigens.	Preclinical (mouse model protection demonstrated).	[56]

Overcoming MDR	Delivery of sensitizing agents or MDR-gene targeting therapeutics (e.g., siRNA).	Encapsulation of therapeutics, potential targeting of resistant cells.	Largely Conceptual/Early Preclinical for specific vault-based MDR reversal strategies.	[1] (general concept)
Synthetic Biology & Nanotechnology				
Nanoscale Containers	General encapsulation of molecules for protection or localized concentration.	Inherent hollow structure, MVP self-assembly.	Established Principle; Used in various research applications.	[9]
Biosensing	Detection of intracellular analytes or environmental monitoring.	Encapsulation of sensor molecules or surface functionalization with recognition elements.	Conceptual/Early Preclinical.	[2]
Enzyme Delivery / Bioremediation	Encapsulation of enzymes for degrading pollutants or catalyzing reactions.	Protection of enzyme activity, potential for targeted delivery or containment.	Preclinical (proof-of-concept for pollutant degradation).	[2]
Nanoscale Electronics	Structural elements for nanomachines, switches for nano-circuits.	Defined structure, potential for ordered assembly.	Highly Conceptual (vision from ~2005).	[32]

The rapid progress in engineering vaults for these diverse applications, especially in medicine, is noteworthy because it is largely proceeding in parallel with, and in some cases even outpacing, the efforts to understand their fundamental native biological

functions. This creates a unique dynamic. The practical knowledge gained from manipulating vault structure for specific nanotechnological outcomes—such as how different MVP modifications affect particle stability, cargo loading efficiency, cellular uptake mechanisms, or interaction with the immune system—can, in turn, generate new hypotheses or provide tools to investigate their natural roles. For example, if modifying the vault cap region, informed by the new structural data from Lövestam and Scheres [21], significantly alters the particle's ability to encapsulate a model drug, it might offer clues about how this region naturally participates in cargo interaction or regulated opening. Thus, the two streams of research—fundamental biology and applied nanotechnology—are not isolated. Discoveries in one domain can fuel experimental designs and insights in the other, potentially creating a synergistic feedback loop that could accelerate our understanding of both the vault's natural purpose and its engineered potential.

Section 7: Future Horizons: Charting the Course for Vault Research

Despite significant advances in understanding vault structure and their potential applications, the core biological function(s) of these enigmatic organelles remain a key challenge. Future research must address critical knowledge gaps using innovative strategies and collaborative efforts.

7.1. Addressing the "Key Challenge": Unanswered Questions and Critical Knowledge Gaps

The foremost unanswered question remains: What is/are the definitive native biological function(s) of vault organelles? Tied to this central query are several specific knowledge gaps that need to be filled:

- **Endogenous Cargo:** The identity of the natural molecular cargo, if any, transported or sequestered by vaults is largely unknown. While some studies suggest mRNA [7], a comprehensive understanding is lacking.
- **Dynamic Mechanisms:** The precise molecular mechanisms by which vaults might open, close, load, and release their cargo *in vivo* are not well understood, although recent structural data on cap pores offer new avenues for investigation.[21]
- **Interactome:** A complete map of the proteins, RNAs, lipids, and other molecules that functionally interact with vaults in different cellular contexts is needed.
- **Critical Conditions:** The specific physiological or pathological conditions under which vault functions become essential for cell survival or optimal performance are not clearly defined.

- **Evolutionary Loss:** The reasons behind the apparent loss of vaults in several successful and complex eukaryotic lineages (e.g., insects, fungi, nematodes, plants) remain speculative and warrant deeper investigation.
- **Molecular Mechanisms of Implicated Roles:** For the many processes vaults are linked to (MDR, immunity, signaling, autophagy, DNA repair), the detailed molecular pathways and the precise contribution of vaults within these pathways require further elucidation.

7.2. Innovative Research Strategies

Addressing these gaps will necessitate the application of cutting-edge and often unbiased research methodologies:

- **Advanced Structural and Imaging Techniques:**
  - Continued application of high-resolution cryo-electron microscopy (cryo-EM), building on studies like that of Lövestam and Scheres [21], will be vital. This includes efforts to capture vaults in different conformational or functional states, potentially with endogenous cargo bound, or in complex with other cellular machinery.
  - The use of advanced live-cell imaging techniques, including super-resolution microscopy, can help track vault dynamics, movement, and interactions within living cells in real-time, providing insights into their transport and localization.[15]
- **Functional Genomics (CRISPR/Cas9 screens) and Proteomics:**
  - CRISPR/Cas9-based functional genomic screens (including knockout, interference (CRISPRi), and activation (CRISPRa) screens) performed in relevant cell types that naturally possess vaults are powerful tools.[60] Such screens can identify genes that show synthetic lethality or other genetic interactions with vault components, thereby uncovering pathways where vaults play a critical role, especially under specific genetic backgrounds or stress conditions.
  - The combination of CRISPR technology with advanced proteomics, such as SWATH (Sequential Window Acquisition of all THeoretical fragment ion spectra) mass spectrometry, allows for the confirmation of protein-level changes post-gene editing and a comprehensive assessment of proteome-wide alterations resulting from the loss or modification of vault components (e.g., MVP knockout in zebrafish).[41]
  - Sophisticated proteomic techniques, including proximity-dependent biotinylation (e.g., BioID) or co-immunoprecipitation coupled with mass spectrometry (Co-IP/MS), can be employed to identify bona fide interacting

partners of vaults and their potential endogenous cargo in an unbiased manner.
    - The application of single-cell proteomics (SCP) could reveal heterogeneity in vault expression, composition, or functional states within a cell population, potentially uncovering specialized roles in specific cell subsets.[59]
- **Focus on VPARP and vtRNAs:**
    - A deeper understanding of the enzymatic activity of VPARP (PARP4) is crucial. Elucidating its substrates, regulatory mechanisms, and how its ADP-ribosylation activity contributes to the overall function of the vault particle is a key area for future research.[17]
    - Further investigation into the diverse roles of vault RNAs (vtRNAs) is warranted. This includes exploring their potential independent functions (separate from the vault particle), the regulation of their expression, their processing into small vault RNAs (svtRNAs), and the mechanisms by which these svtRNAs might be involved in gene silencing or other regulatory processes.[1]

The path towards finally deciphering vault function likely lies in a synergistic approach. Combining unbiased, system-wide "discovery" tools like CRISPR screens and comprehensive proteomics with traditional hypothesis-driven investigations will be powerful. Crucially, these studies must be conducted under a broader range of physiological and stress conditions than previously explored. Moreover, focusing these efforts on model organisms that naturally possess vaults, even if they are less conventional than yeast or flies (e.g., *Dictyostelium*, zebrafish, or specific mammalian cell lines that robustly express vaults), will be paramount. The subtle phenotypes often observed in knockout mice under standard laboratory conditions suggest that vaults may play roles that are only critical or apparent under specific environmental challenges or in particular developmental contexts. Unbiased screening methods applied to these systems under varied conditions can generate new, robust hypotheses that can then be tested with more focused experiments, breaking the cycle of inconclusive findings.

7.3. The Importance of Interdisciplinary Collaboration and Public Engagement

Solving the vault mystery will likely require extensive interdisciplinary collaboration, bringing together cell biologists, structural biologists, biochemists, geneticists, immunologists, cancer biologists, and nanotechnologists. Each discipline offers unique perspectives and tools that can contribute to a more holistic understanding.
Public engagement and outreach are also important for fostering interest and inspiring a new generation of researchers to tackle this longstanding puzzle. Efforts such as Dr. Leonard Rome's "The Vault Guy" YouTube channel aim to educate a broader audience about cell

biology through the story of vault discovery and characterization, highlighting their existence and the ongoing quest to understand them.3 Such initiatives can play a role in ensuring that these fascinating organelles do not remain overlooked in cell biology education and research.

Section 8: Conclusion: The Vault – A Testament to Biology's Complexity and Potential

8.1. Recap of the Vault as a Significant, Unsolved Puzzle

The eukaryotic vault organelle stands as a testament to the intricate complexity of the cell and represents one of contemporary biology's most fascinating and enduring unsolved puzzles. Discovered serendipitously nearly four decades ago, its unique barrel-shaped architecture, remarkable evolutionary conservation across diverse eukaryotic lineages, and sheer abundance within cells all point towards significant, yet still largely undefined, biological roles. Despite extensive research into its structure, composition, and numerous implicated cellular processes, the fundamental native function(s) of the vault remain actively sought.

8.2. The Dual Nature of Vaults: Fundamental Biological Entities and Versatile Nanotechnological Tools

A remarkable dichotomy defines the current state of vault research. While their intrinsic biological purpose continues to be a subject of intense investigation and debate, their well-defined structure, inherent biocompatibility, and the capacity for self-assembly from the Major Vault Protein have rendered them an exceptionally promising and versatile platform for a wide array of nanotechnological and biomedical applications. The ability to engineer vaults to encapsulate therapeutic agents, deliver genes, present antigens for vaccines, and serve as nanoscale scaffolds is rapidly advancing, showcasing a translation from biological mystery to tangible technological innovation.

8.3. Concluding Remarks on the Imperative and Promise of Continued Investigation

The journey to unlock the secrets of the vault organelle is far from over. Continued, rigorous fundamental research is imperative. Solving this "key challenge" in eukaryote biology will not only profoundly expand our understanding of basic cellular mechanisms, intracellular transport, stress responses, and signaling networks but also holds the potential to unveil new paradigms relevant to human health and disease. Furthermore, a deeper comprehension of their natural functions will undoubtedly inform and refine their already promising applications in nanotechnology and medicine. The persistent enigma of the vault underscores the vastness of biological intricacies yet to be discovered and the profound potential that lies in dedicated

scientific inquiry in service of both knowledge and humanity.

Works cited

1. Vault Particles in Cancer Progression, Multidrug Resistance, and Drug Delivery: Current Insights and Future Applications - PubMed Central, accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11855390/
2. Vault (organelle) - Wikipedia, accessed June 1, 2025, https://en.wikipedia.org/wiki/Vault_(organelle)
3. Biologist Aims to Solve Cell's Biggest Mystery: Vaults - AHB Lab, accessed June 1, 2025, https://www.ahb-lab.com/en_us/news/biologist-aims-to-solve-cells-biggest-mystery-vaults/
4. The key to 'the vault' - Royal Society of Biology, accessed June 1, 2025, https://www.rsb.org.uk/biologist-features/unlocking-the-vault
5. A Vaulted Mystery | The Scientist, accessed June 1, 2025, https://www.the-scientist.com/a-vaulted-mystery-37086
6. en.wikipedia.org, accessed June 1, 2025, https://en.wikipedia.org/wiki/Vault_(organelle)#:~:text=Discovered%20and%20isolated%20by%20Nancy,(or%20D39d)%20symmetry.
7. In Silico Resurrection of the Major Vault Protein Suggests It Is ..., accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3762200/
8. en.wikipedia.org, accessed June 1, 2025, https://en.wikipedia.org/wiki/Vault_(organelle)#:~:text=Although%20vaults%20have%20been%20observed,nematode%20that%20lives%20in%20soil.
9. Vault Nanoparticles Engineered with the Protein Transduction Domain, TAT48, Enhances Cellular Uptake - PMC, accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3704152/
10. The Vault Complex Is Significantly Involved in Therapeutic Responsiveness of Endocrine Tumors and Linked to Autophagy under Chemotherapeutic Conditions, accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10046419/
11. May 27, 2024 | The key to 'the vault' - California NanoSystems Institute, accessed June 1, 2025, https://cnsi.ucla.edu/may-27-2024-the-key-to-the-vault/
12. Molecule of the Month: Vaults - PDB-101, accessed June 1, 2025, https://pdb101.rcsb.org/motm/114
13. June 6, 2024 | The Vault Guy - California NanoSystems Institute - UCLA, accessed June 1, 2025, https://cnsi.ucla.edu/june-6-2024-the-vault-guy/
14. Cell vaults: the next big thing in biology?, accessed June 1, 2025, https://www.cellgs.com/blog/cell-vaults-the-next-big-thing-in-biology.html
15. Structure, Dynamics and Functional Implications of the Eukaryotic Vault Complex | Request PDF - ResearchGate, accessed June 1, 2025, https://www.researchgate.net/publication/381999555_Structure_Dynamics_and_Functional_Implications_of_the_Eukaryotic_Vault_Complex
16. Evolution of Vault RNAs - Oxford Academic, accessed June 1, 2025, https://academic.oup.com/mbe/article/26/9/1975/1190642

17. VPARP as a sequestered enzyme within the vault complex - Article abstract #15087 - Medical Science Monitor, accessed June 1, 2025, https://medscimonit.com/abstract/index/idArt/15087
18. Vault (organelle) | 504 Publications | 3127 Citations | Top Authors | Related Topics - SciSpace, accessed June 1, 2025, https://scispace.com/topics/vault-organelle-rcaz0t0z
19. Major Vault Protein is Expressed along the Nucleus–Neurite Axis ..., accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2693621/
20. MVP and vaults: a role in the radiation response - PMC, accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3216873/
21. (PDF) Cryo-EM structure of the vault from human brain reveals symmetry mismatch at its caps - ResearchGate, accessed June 1, 2025, https://www.researchgate.net/publication/392148448_Cryo-EM_structure_of_the_vault_from_human_brain_reveals_symmetry_mismatch_at_its_caps
22. (PDF) Expression profiles of vault components MVP, TEP1 and vPARP and their correlation to other multidrug resistance proteins in ovarian cancer - ResearchGate, accessed June 1, 2025, https://www.researchgate.net/publication/237059711_Expression_profiles_of_vault_components_MVP_TEP1_and_vPARP_and_their_correlation_to_other_multidrug_resistance_proteins_in_ovarian_cancer
23. Vault poly(ADP-ribose) polymerase is associated with mammalian telomerase and is dispensable for telomerase function and vault structure in vivo - PubMed, accessed June 1, 2025, https://pubmed.ncbi.nlm.nih.gov/15169895/
24. vPARP Adjusts MVP Expression in Drug-resistant Cell Lines in Conjunction with MDR Proteins | Anticancer Research, accessed June 1, 2025, https://ar.iiarjournals.org/content/37/6/3015
25. The Telomerase/Vault-Associated Protein Tep1 Is Required for Vault ..., accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2193651/
26. pmc.ncbi.nlm.nih.gov, accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2193651/#:~:text=Our%20findings%20indicate%20that%20TEP1,vRNA%20association%20with%20vault%20particles.
27. Vault RNA - Wikipedia, accessed June 1, 2025, https://en.wikipedia.org/wiki/Vault_RNA
28. pmc.ncbi.nlm.nih.gov, accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1201340/#:~:text=The%20vRNA%20ends%20(5%E2%80%B2%20and,RNA%20or%20RNA%E2%80%93protein%20interactions.
29. Cryo-EM structure of the vault from human brain reveals symmetry ..., accessed June 1, 2025, https://www.biorxiv.org/content/10.1101/2025.05.27.656403v1
30. Vaults: A ribonucleoprotein particle involved in drug resistance ..., accessed June 1, 2025, https://www.researchgate.net/publication/231587827_Vaults_A_ribonucleoprotein_particle_involved_in_drug_resistance
31. Understanding the role of vault ribonucleoprotein particles in the context of viral infection, accessed June 1, 2025,

https://ung.si/en/research/laboratory-for-environmental-and-life-sciences/projects/understanding-the-role-of-vault/
32. Vaults: From Biological Mystery to Nanotech Workhorse? - National Science Foundation, accessed June 1, 2025, https://www.nsf.gov/news/vaults-biological-mystery-nanotech-workhorse
33. Assembly of Nuclear Pore Complexes Mediated by Major Vault Protein, accessed June 1, 2025, https://pubmed.ncbi.nlm.nih.gov/19240118/
34. en.wikipedia.org, accessed June 1, 2025, https://en.wikipedia.org/wiki/Vault_(organelle)#:~:text=Vaults%20have%20been%20implicated%20in,pore%20assembly%2C%20and%20innate%20immunity.
35. 9961 - Gene ResultMVP major vault protein [(human)] - NCBI, accessed June 1, 2025, https://www.ncbi.nlm.nih.gov/gene/9961
36. Vault Particles in Cancer Progression, Multidrug Resistance, and ..., accessed June 1, 2025, https://www.mdpi.com/1422-0067/26/4/1562
37. www.ncbi.nlm.nih.gov, accessed June 1, 2025, https://www.ncbi.nlm.nih.gov/gene/9961#:~:text=Major%20vault%20protein%20regulates%20tumor,via%20mTOR%2FS6K1%20signaling%20cascade.
38. pmc.ncbi.nlm.nih.gov, accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10914904/#:~:text=Vault%20particles%20can%20affect%20the,into%20dendritic%20cells%20(DCs).
39. Crosstalk between vault RNAs and innate immunity - PMC, accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10914904/
40. mvpA - Major vault protein alpha - Dictyostelium discoideum (Social amoeba) | UniProtKB | UniProt, accessed June 1, 2025, https://www.uniprot.org/uniprotkb/P34118/entry
41. Confirming Gene Mutation by CRISPR-Cas9 at the Protein Level using SWATH Acquisition, accessed June 1, 2025, https://crisprmedicinenews.com/fileadmin/user_upload/Editor/Confirming_Gene_Silencing_with_CRISPR-Cas9_at_the_Protein_Level_Using_SWATH_R__Acquisition_on_TripleTOF_R__Systems.PDF
42. Structural and Functional Studies of Molecular Machines Involved in Chemical Modifications of Macromolecules - NIH RePORTER, accessed June 1, 2025, https://reporter.nih.gov/project-details/10880606
43. Vault Particles in Cancer Progression, Multidrug Resistance, and Drug Delivery: Current Insights and Future Applications - OUCI, accessed June 1, 2025, https://ouci.dntb.gov.ua/en/works/lxLr5BwE/
44. Organelle-Targeting Nanoparticles - PubMed, accessed June 1, 2025, https://pubmed.ncbi.nlm.nih.gov/39806939/
45. Recent Update on siRNA Therapeutics - PMC - PubMed Central, accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12026779/
46. Nanoparticles co-delivering siRNA and mRNA for simultaneous restoration and silencing of gene/protein expression in vitro and in vivo | bioRxiv, accessed June 1, 2025, https://www.biorxiv.org/content/10.1101/2024.06.22.600196v1.full-text
47. The landscape of nanoparticle-based siRNA delivery and therapeutic development - PMC, accessed June 1, 2025,

https://pmc.ncbi.nlm.nih.gov/articles/PMC10861989/
48. Nanotechnology-Enhanced siRNA Delivery: Revolutionizing Cancer Therapy - PubMed, accessed June 1, 2025, https://pubmed.ncbi.nlm.nih.gov/40354673/
49. mRNA Delivery of Gene Therapy using Extracellular Vesicles Produces Better Immune Response than AAV and LNP Delivery - Stanford Medicine, accessed June 1, 2025, https://med.stanford.edu/content/sm/cvi/mission/news_center/articles_announcements/2025/mrna-gene-therapy-using-extracellular-vesicles-for-better-immune-response.html
50. Engineering Lipid Nanoparticles for mRNA Immunotherapy - PMC, accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11976204/
51. Encapsulation of AAVs into protein vault nanoparticles as a novel ..., accessed June 1, 2025, https://www.biorxiv.org/content/10.1101/2023.11.29.569229v4
52. 2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline, accessed June 1, 2025, https://www.globenewswire.com/news-release/2025/03/04/3036739/28124/en/2025-Market-Prospects-of-Adeno-Associated-Virus-Vectors-in-Gene-Therapy-Pipeline-200-Pipeline-Drugs-and-the-Strategic-Workings-of-180-Companies.html
53. Advances in Gene Therapy for Rare Diseases: Targeting Functional Haploinsufficiency Through AAV and mRNA Approaches - PubMed Central, accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11765483/
54. Dendritic Cells and CCR7 Expression: An Important Factor for Autoimmune Diseases, Chronic Inflammation, and Cancer - MDPI, accessed June 1, 2025, https://www.mdpi.com/1422-0067/22/15/8340?type=check_update&version=1
55. Vault Pharma, accessed June 1, 2025, https://vaultpharma.com/
56. TEDxUCLA - Leonard Rome - Vaults.mov - YouTube, accessed June 1, 2025, https://www.youtube.com/watch?v=om1H64OMKzM
57. Nucleic Acid Framework-Enabled Spatial Organization for Biological Applications | Chem & Bio Engineering - ACS Publications, accessed June 1, 2025, https://pubs.acs.org/doi/10.1021/cbe.4c00164
58. www.nsf.gov, accessed June 1, 2025, https://www.nsf.gov/news/news_summ.jsp?cntn_id=104506
59. Organelle Omics Analysis and Applications - Creative Proteomics, accessed June 1, 2025, https://www.creative-proteomics.com/blog/index.php/organelle-omics-analysis-and-applications/
60. CRISPR-based functional genomics screening in human-pluripotent-stem-cell-derived cell types - PMC, accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10203043/
61. CRISPR screens unveil nutrient-dependent lysosomal and mitochondrial nodes impacting intestinal tissue-resident memory CD8+ T cell formation - PubMed Central, accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11590283/
62. Single-Cell Proteomics using Mass Spectrometry - PMC, accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11875278/

63. Vault RNAs: hidden gems in RNA and protein regulation - PMC - PubMed Central, accessed June 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7904556/
64. Physical Science – California NanoSystems Institute - UCLA, accessed June 1, 2025, https://cnsi.ucla.edu/category/physical-science/
65. Episode 9: Vaults...Now in 3D - YouTube, accessed June 1, 2025, https://www.youtube.com/watch?v=OuZpzic9pAg
66. The Vault Guy - YouTube, accessed June 1, 2025, https://www.youtube.com/@VaultParticleGuy